Friday, December 13, 2019

Arrowhead Pharmaceuticals Names New Director

Pasadena-based Arrowhead Pharmaceuticals announced this morning that it has named Marianne De Backer, Ph.D., as an independent director for the company. Backer is Executive Vice President, Head of Global Business Development & Licensing, and a member of the Executive Committee of the Pharmaceuticals Division of Bayer AG, and she also served at Johnson & Johnson. Arrowhead Pharmaceuticals is working on gene silencing technology using RNA interference (RNAi), which has possible applications in treatments of a number of conditions. Arrowhead recently raised $288.6M in a public offering.